早期非小细胞肺癌合并间质性肺病根治性放疗的毒性及结局:系统综述与剂量学分析
该系统综述纳入24项研究共705例合并间质性肺病(ILD)的早期非小细胞肺癌(ES-NSCLC)患者,接受根治性放疗。治疗相关死亡风险为7.9%,严重治疗相关呼吸毒性为15.7%,肺V5较高与死亡显著相关。3年局部控制率76%,中位总生存2.5年。
要点
- 合并ILD的ES-NSCLC患者根治性放疗治疗相关死亡风险7.9%,严重呼吸毒性15.7%。
- 肺V5较高与死亡风险显著相关,需关注剂量学参数。
- 3年局部控制率76%,中位总生存2.5年。
核心结论
- 合并ILD的ES-NSCLC患者根治性放疗需权衡治疗相关死亡与毒性风险。
- 未来研究应统一报告ILD特征以助风险分层。
研究设计与样本
- 遵循PRISMA指南的系统综述,检索PubMed、EMBASE和Cochrane Library从建库至2024年6月。
- 纳入24项研究,共705例接受根治性单纯放疗的ILD合并ES-NSCLC患者。
主要发现
- 71%(n=502)患者未报告具体ILD亚型,62%(n=440)未报告ILD严重程度。
- 治疗相关死亡风险为7.9%,严重治疗相关呼吸毒性为15.7%。
- 较高肺V5与死亡显著相关。
- 3年局部控制率为76%,中位总生存为2.5年。
关键数值与推荐
- 治疗相关死亡风险7.9%,严重治疗相关呼吸毒性15.7%。
- 3年局部控制率76%,中位总生存2.5年。
- 肺V5较高与死亡显著相关。
临床怎么用
- 对合并ILD的ES-NSCLC患者行根治性放疗前应评估ILD特征及剂量学参数如肺V5。
- 需充分告知患者治疗相关死亡和严重呼吸毒性风险。
局限性
- 多数患者未报告ILD亚型(71%)和严重程度(62%),限制风险分层。
- 系统综述基于现有研究,可能存在异质性和报告偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with interstitial lung disease (ILD) who develop lung cancer represent a unique challenge, as they are at higher risk for serious toxicity from local and systemic therapies. The aim of this study is to provide an up-to-date analysis on toxicities and outcomes associated with definitive radiation therapy (RT) in patients with ILD and early-stage non-small cell lung cancer (ES-NSCLC). METHODS AND MATERIALS: We performed a systematic review in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The PubMed (MEDLINE), EMBASE, and Cochrane Library databases were searched from inception until June 2024, for studies including patients with ILD who underwent definitive RT alone for ES-NSCLC. Data including treatment-related mortality, toxicity, local control, and overall survival were collected and analyzed. RESULTS: Of 3545 records reviewed, 24 studies were identified for full data abstraction, contributing a total of 705 patients. A specific ILD subtype was not reported for 71% (n = 502) of patients. ILD severity was not reported for 62% (n = 440) of patients. Risk of treatment-related mortality was 7.9%, with severe treatment-related respiratory toxicity 15.7%. A higher volume of lung receiving ≥5 Gy (V5) was significantly correlated with mortality. The estimated local control at 3 year was 76% and median overall survival was 2.5 years. CONCLUSIONS: The relative merits of RT for the treatment of ES-NSCLC in patients with ILD should be considered in the context of the rates of treatment-related mortality and toxicity. Future studies would benefit from consistent reporting of ILD characteristics, which may help in risk stratification in this challenging clinical scenario.
引用
- Li GJ, Soon MS, Chen H, et al. Treatment Toxicity and Outcomes Following Definitive Radiation Therapy for Patients With Early-Stage Non-Small Cell Lung Cancers and Pre-Existing Interstitial Lung Disease-A Systematic Review and Dosimetric Analysis. Int J Radiat Oncol Biol Phys. 2025. PMID: 40581332. doi:10.1016/j.ijrobp.2025.06.3854
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。